Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isao Asakawa

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
Nihon Rinsho. Japanese Journal of Clinical Medicine|January 3, 2012
[Acute and late toxicities and its management]Isao Asakawa, Masatoshi Hasegawa
Nihon Rinsho. Japanese Journal of Clinical Medicine|April 15, 2014
[Radiation therapy for malignant lymphoma]Isao Asakawa, Tetsuro Tamamoto, Masatoshi Hasegawa
Brachytherapy|December 3, 2014
Urethral toxicity after LDR brachytherapy: experience in JapanNobumichi Tanaka, Isao Asakawa, Masatoshi Hasegawa, et al.
Nihon Rinsho. Japanese Journal of Clinical Medicine|July 5, 2006
[Radiation injury to the testis]Masatoshi Hasegawa, Isao Asakawa, Takayuki Shinkai, et al.
Nihon Rinsho. Japanese Journal of Clinical Medicine|February 7, 2006
[Radiotherapy for carcinomas of the biliary tract]Tetsuro Tamamoto, Isao Asakawa, Masatoshi Hasegawa, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|September 25, 2019
Low-dose-rate brachytherapy for prostate cancer: A 15-year experience in JapanNobumichi Tanaka, Isao Asakawa, Masatoshi Hasegawa, et al.
Journal of Gynecologic Oncology|October 30, 2013
Posttreatment cut-off levels of squamous cell carcinoma antigen as a prognostic factor in patients with locally advanced cervical cancer treated with radiotherapyRyuji Kawaguchi, Naoto Furukawa, Hiroshi Kobayashi, et al.
Urology|April 21, 2009
Variations in international prostate symptom scores, uroflowmetric parameters, and prostate volume after (125)I permanent brachytherapy for localized prostate cancerNobumichi Tanaka, Kiyohide Fujimoto, Yoshihiko Hirao, et al.
Brachytherapy|October 5, 2024
Prostate-specific antigen (PSA) nadir and experience of PSA bounce after low-dose-rate brachytherapy for prostate cancer predicts clinical failureYasushi Nakai, Nobumichi Tanaka, Isao Asakawa, et al.
Radiation Oncology (London, England)|June 3, 2014
The biochemical recurrence-free rate in patients who underwent prostate low-dose-rate brachytherapy, using two different definitionsNobumichi Tanaka, Isao Asakawa, Emiko Katayama, et al.
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
Nihon Rinsho. Japanese Journal of Clinical Medicine|January 3, 2012
[Acute and late toxicities and its management]Isao Asakawa, Masatoshi Hasegawa
Nihon Rinsho. Japanese Journal of Clinical Medicine|April 15, 2014
[Radiation therapy for malignant lymphoma]Isao Asakawa, Tetsuro Tamamoto, Masatoshi Hasegawa
Brachytherapy|December 3, 2014
Urethral toxicity after LDR brachytherapy: experience in JapanNobumichi Tanaka, Isao Asakawa, Masatoshi Hasegawa, et al.
Nihon Rinsho. Japanese Journal of Clinical Medicine|July 5, 2006
[Radiation injury to the testis]Masatoshi Hasegawa, Isao Asakawa, Takayuki Shinkai, et al.
Nihon Rinsho. Japanese Journal of Clinical Medicine|February 7, 2006
[Radiotherapy for carcinomas of the biliary tract]Tetsuro Tamamoto, Isao Asakawa, Masatoshi Hasegawa, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|September 25, 2019
Low-dose-rate brachytherapy for prostate cancer: A 15-year experience in JapanNobumichi Tanaka, Isao Asakawa, Masatoshi Hasegawa, et al.
Journal of Gynecologic Oncology|October 30, 2013
Posttreatment cut-off levels of squamous cell carcinoma antigen as a prognostic factor in patients with locally advanced cervical cancer treated with radiotherapyRyuji Kawaguchi, Naoto Furukawa, Hiroshi Kobayashi, et al.
Urology|April 21, 2009
Variations in international prostate symptom scores, uroflowmetric parameters, and prostate volume after (125)I permanent brachytherapy for localized prostate cancerNobumichi Tanaka, Kiyohide Fujimoto, Yoshihiko Hirao, et al.
Brachytherapy|October 5, 2024
Prostate-specific antigen (PSA) nadir and experience of PSA bounce after low-dose-rate brachytherapy for prostate cancer predicts clinical failureYasushi Nakai, Nobumichi Tanaka, Isao Asakawa, et al.
Radiation Oncology (London, England)|June 3, 2014
The biochemical recurrence-free rate in patients who underwent prostate low-dose-rate brachytherapy, using two different definitionsNobumichi Tanaka, Isao Asakawa, Emiko Katayama, et al.
Pageof 7